| Literature DB >> 34768150 |
Samuel C Eggenberger1, Natalie L James2, Cherry Ho2, Steven S Eamegdool3, Veronika Tatarinoff2, Naomi A Craig2, Barry S Gow2, Susan Wan4, Christopher W D Dodds2, Donna La Hood5, Aaron Gilmour6, Shannon L Donahoe7, Mark Krockenberger7, Krishna Tumuluri8, Melville J da Cruz9, John R Grigg10, Peter McCluskey10, Nigel H Lovell2, Michele C Madigan11, Adrian T Fung8, Gregg J Suaning12.
Abstract
Severe visual impairment can result from retinal degenerative diseases such as retinitis pigmentosa, which lead to photoreceptor cell death. These pathologies result in extensive neural and glial remodelling, with survival of excitable retinal neurons that can be electrically stimulated to elicit visual percepts and restore a form of useful vision. The Phoenix99 Bionic Eye is a fully implantable visual prosthesis, designed to stimulate the retina from the suprachoroidal space. In the current study, nine passive devices were implanted in an ovine model from two days to three months. The impact of the intervention and implant stability were assessed using indirect ophthalmoscopy, infrared imaging, and optical coherence tomography to establish the safety profile of the surgery and the device. The biocompatibility of the device was evaluated using histopathological analysis of the tissue surrounding the electrode array, with a focus on the health of the retinal cells required to convey signals to the brain. Appropriate stability of the electrode array was demonstrated, and histological analysis shows that the fibrotic and inflammatory response to the array was mild. Promising evidence of the safety and potential of the Phoenix99 Bionic Eye to restore a sense of vision to the severely visually impaired was obtained.Entities:
Keywords: Biocompatibility; Histopathology; Surgical safety; Visual prosthesis
Mesh:
Year: 2021 PMID: 34768150 DOI: 10.1016/j.biomaterials.2021.121191
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479